



## PRESS RELEASE

**ABOUT 4.2 MILLION OF ORABLOC® INJECTORS SOLD IN THE US IN Q1 2018  
(+19% COMPARED TO THE SAME PERIOD IN 2017 (Y/Y))**

**NEW AGREEMENTS FOR THE DISTRIBUTION OF ORABLOC® IN CANADA AND  
SUDAN WERE SIGNED**

**THE MARKETING OF THE GOCCLES® MEDICAL DEVICE FOR THE  
SCREENING OF ORAL CANCER WAS STARTED**

*Capua (CE), 4 May 2018* – **Pierrel S.p.A.** (the "**Company**") announces that during the first quarter of 2018 its subsidiary Pierrel Pharma S.r.l. with sole shareholder ("**Pierrel Pharma**"), a holding company of the Pierrel Group's Pharma Division, active in the marketing and distribution of medicinal products, as well as in the development and management of the authorisations of the Pierrel Group for the marketing of medicines, has registered retail sales in the United States for about 4.2 million of **Orabloc®** injectors (anesthetic for dental use based on articaine produced in the plant owned by the company in Capua (CE)). This figure, which confirms the constant growth and continuous appreciation of the Orabloc® anesthetic (see, among others, the press releases published by the Company on 30 January 2017, 20 July 2016 and 28 June 2016, all available on the website of the Company at [www.pierrelgroup.com](http://www.pierrelgroup.com), section *Press/Press Releases*) registered, especially in the North American market, since 2011, the year of the launch of its marketing, represents a growth of about 19% compared to the sales of Orabloc® in the US market registered by Pierrel Pharma in the first quarter of 2017.

In addition, in April 2018, Pierrel Pharma obtained new marketing authorisations for the **Orabloc®** dental anesthetic in Canada and Sudan, markets in which the distribution should start this year, and which will then join the more recently acquired markets in which the dental anesthetic is already distributed, including the United Kingdom (where the distribution, started in April 2018, is carried out by DentalSky, a distributor linked to Pierrel Pharma by an exclusive agreement) and Taiwan (where the distribution, started in November 2017, is carried out by the local distributor Majorpharm, also linked to Pierrel Pharma by an exclusive agreement).

Finally, the Company announces that, after having internalized the operational management of sales and marketing, Pierrel Pharma has started marketing in the Italian market and in the United States, United Kingdom and Canada its medical device for oral cancer screening called **GOCCLES®** on the basis of non-exclusive distribution contracts signed with some of the commercial partners already involved in the distribution of Orabloc in the US (Patterson Dental, Benco Dental, Henry Schein dental and Atlanta Dental), in the United Kingdom (DentalSky) and Canada (Patterson Dental).

\* \* \*



**Pierrel S.p.A.** specialises in the pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).

Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years' experience in the pharmaceutical sector, being one of Europe's leading producers of local and dental anaesthetics.

Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines.

The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe. The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

**For further information:**

**Pierrel S.p.A.**

*Investor Relations*

Mr Fulvio Citaredo

E-mail: [investor.relations@pierrelgroup.com](mailto:investor.relations@pierrelgroup.com)

tel. +39 0823 626 111

fax +39 0823 626 228

**Global Consult s.r.l.**

*Media Relations*

Rossana Del Forno

E-mail: [areacomunicazione@globalconsultsrl.com](mailto:areacomunicazione@globalconsultsrl.com)

tel. +39 333 6178665